Regeneron can't get injunction against Amgen over eye medication, US appeals court says
The US Court of Appeals for the Federal Circuit affirmed Friday that Regeneron is not likely to succeed on the merits in patent litigation against Amgen over its eye medication Eylea,...To view the full article, register now.
Already a subscriber? Click here to view full article